Moataz Yousry Soliman

Verified @azhar.edu.eg

Moataz Yousry Soliman


            Download Compact PDF  
https://researchid.co/moatazyousry
10

Scopus Publications

76

Scholar Citations

5

Scholar h-index

2

Scholar i10-index

Scopus Publications

  • Flaxseed oil and probiotics protect against induced nonalcoholic fatty liver disease (NAFLD) in male rats
    Haddad A. El Rabey, Maha J. Balgoon, Mohammed A. Alsieni, Adel I. Alalawy, Moataz Y. Soliman, Mohamed M. El Hoseeny, Samar M. Rezk, Nadia Bakry
    Open Life Sciences, 2026
    This study aimed to evaluate the effect of probiotics and flaxseed oil on nonalcoholic fatty liver disease (NAFLD). 50 male albino rats were divided into five groups (10/each), the 1st negative control group fed on the basal diet (G1) and four other groups subjected to induced NAFLD and then classified into four groups; the 2nd positive control group induced-Non Alcoholic fatty liver disease (G2), the 3rd group was treated with flaxseed oil (G3), the 4th group was treated with live probiotics (G4) and the 5th group was treated with mixed of flaxseed oil and live probiotics (G5). The study was conducted for 8 weeks. GC analysis indicated that the main constituent of flaxseed oil is the omega-3 fatty acid α-linolenic acid methyl ester (44.89 %). The positive control group showed severely altered lipid profile, liver enzymes, transforming growth factor-β (TGF-β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and liver histology, whereas treating the NAFLD with flaxseed oil or probiotic strains or their mix significantly improved lipid profile, liver enzyme, transforming growth factor-β (TGF-β), inflammatory markers (tumor necrosis factor-α (TNF-α) and interleukin-6 “IL-6”), and significantly decreased oxidative stress levels than the positive control group. Flaxseed oil and probiotics, separately and in combination, confer hepatoprotective effects against induced NAFLD in rats.
  • A comparative survey study of knowledge, attitude, and practice towards medical ethics among surgical and non-surgical physicians
    Heba K. Khalifa, Amira A. Wahdan, Moataz Y. Soliman, Fatma G. Sobeeh
    Egyptian Journal of Forensic Sciences, 2024
    Background Medical ethics is the ethical branch that deals with moral concerns through the application of certain standards and principles in medical practice. With the vast development in medical and surgical practice, a lot of ethical issues arose. This cross-sectional study aimed to compare physicians from surgical and non-surgical departments (303 and 243 physicians respectively) regarding their knowledge, practice, and attitude toward medical ethics. It was carried out at Tanta University Hospital, using both online and printed questionnaires that included socio-demographic data, subscales designed to evaluate knowledge (15 questions), attitude and practice (15 more questions) about medical ethics. Descriptive statistics were performed to assess the relations between different study variables. Results A total of 546 participants completed the questionnaire, with 55.5% from non-surgical departments and 44.5% from surgical departments. The demographic analysis revealed no statistically significant differences. The results of the study showed that the non-surgical group exhibited higher levels of knowledge compared to the surgical group. The non-surgical group demonstrated higher compliance with ethical practices compared to the surgical group. Logistic regression analysis confirmed the association between specialty and knowledge/practice levels, with higher qualifications and professional positions correlating with better knowledge and practice. Conclusion This study highlights the variations in knowledge, attitude, and practice of medical ethics among physicians in non-surgical and surgical departments. Further efforts are required to enhance ethical education and promote consistent ethical practices.
  • Covert hepatic encephalopathy: a neglected topic—a narrative review
    Mohamed Elbadry, Amin Abdel Baki, Asmaa bakr, Eman A. Elhamrawy, Hayam Abdel-Tawab, Abdelghany Aish, Israa Nooh, Abdulmoneim Adel, Moataz Y. Soliman, Nessren Mohammed, Samy Zaky
    Egyptian Liver Journal, 2024
    Covert hepatic encephalopathy (CHE) is a form of cerebral dysfunction that affects 30–40% of patients with liver cirrhosis as a grave sequel of disease progression. Although being a silent condition, yet; CHE has been reported as seriously predictive for the development of overt hepatic encephalopathy. Covert hepatic encephalopathy is said to conclude grades (0 and 1) hepatic encephalopathy in West Heaven grading of hepatic encephalopathy, hence; inferring to discrete deficits in attention, cognition, and motor control, strongly associated with poorer quality of private and social aspects of the patients’ life. Clinical recognition of cases of CHE is such a tedious task that unluckily devoid of discernment. Worthwhile; the battery of neuropsychometric tests widely known as the only tool to identify CHE can give abnormal results without specifying the cause of brain dysfunction Therefore, dedicated history-taking and clinical evaluation of liver cirrhosis patients are still the cornerstones that should unify other diagnostic tools to identify those patients at risk of developing overt hepatic encephalopathy. Diagnosis of CHE is challenging and often neglected in clinical practice, so the aim of this review is to improve our approach to CHE and begin a unified effort for the advancement of CHE through studying easy, fast, and reliable psychometric diagnostic tests to meet our clinical needs.
  • Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysis
    Hazem Abosheaishaa, Mai Hussein, Muhammad Ghallab, Magdy Abdelhamid, Natalie Balassiano, Md Ripon Ahammed, Muhammad Almas Baig, Jawad Khan, Moaz Elshair, Moataz Yousry Soliman, Mohammed Abdelwahed, Amr Ali, Ahmed Alzamzamy, Mahmoud Nassar
    Diabetes and Metabolic Syndrome Clinical Research and Reviews, 2024
  • The Value of Thioredoxin Level and its Gene Polymorphism in the Diagnosis of Post-HCV Hepatocellular Carcinoma
    Sherief Abd-Elsalam, Hatem Samir Alegaily, Moataz Yousry Soliman, Ahmed Mehrez Gad, Eid Abdel-Monsef Abou-Omar, Mohamed Saleh, Raghda Samir Abdellatif, Amina Fouad, Omar Mahmoud Azzam, Yousry Esam-Eldin Abo-Amer
    Current Cancer Therapy Reviews, 2023
    Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies and a leading cause of cancer-related death worldwide. Indeed, we need a novel tumor marker other than AFP for early detection and to improve the outcome. Serum thioredoxin is a promising protein involved in the pathogenesis of many malignancies. The study aims to evaluate serum thioredoxin and its gene polymorphism in HCC in cirrhotic patients due to HCV infection. Patients and Methods: 350 patients with HCC, 350 patients with chronic liver diseases, and 300 healthy controls were enrolled in our study. Serum thioredoxin level was measured by ELISA, and molecular study of thioredoxin domain-containing 5 (TXNDC5) gene polymorphism (rs1225943) polymorphism using real-time polymerase chain reaction by Taqman allele discrimination was done for all subjects. Results: Our study revealed a significant increase in serum thioredoxin levels in patients with HCC compared to chronic liver diseases and healthy controls. Using the Receiver operating characteristic (ROC) curve at the area under the curve (AUC) 0.917 and a cut-off value of > 14.6 U/ml, our overall sensitivity and specificity for the HCC group over the other groups were 86 % and 92.15%, respectively with 92.2% positive predictive value and 54.9% negative predictive value. The molecular study of TXNDC5 gene polymorphism (rs1225943) polymorphism revealed no significant difference between the studied groups. Conclusion: Serum thioredoxin may be used as a promising tumor marker for HCC. Future research is needed to assess its use as a single or combined with other markers in the diagnosis and follow-up of the patients after interventions.
  • Association Between Vitamin D Receptor Polymorphism and the Response to Helicobacter Pylori Treatment
    Yousry Esam-Eldin Abo-Amer, Amal Ahmed Mohamed, Mohamed Mahmoud Elhoseeny, Samar M Rezk, Sherief Abdel-Salam, Abdulmohsen H Alrohaimi, Asmaa Sayed Abdelgeliel, Seham Saeed Alzahrani, Ibrahim Jafri, Leena S Alqahtani, Eman Fayad, Mohamed Fakhry, Moataz Yousry Soliman
    Infection and Drug Resistance, 2023
    Background & Aims This research aimed to determine how variations in the vitamin D receptor gene affected the response of H. pylori infections to eradication therapy. Patients and Methods On 105 adult H. Pylori-positive patients, a prospective cohort study was carried out. PCR was used to genotype all patients’ VDR gene polymorphisms. The patients in the study received standard triple eradication medication (clarithromycin 500 mg, amoxicillin 1000 mg, and omeprazole 20 mg) twice daily for 14 days. A stool test for H. pylori Ag was conducted 4 weeks following the end of treatment. Results In our study, the usual triple therapy’s H. pylori eradication rate was 75.2%. The successful eradication of H. pylori and VDR rs 2228570 gene polymorphisms was more prevalent in CT gene polymorphism (64.6%) compared to non-responders (19.2%), while treatment failure was more prevalent in CC gene polymorphism (73.1% in non-responders compared to responders 24.1%), which is statistically significant. In regards to the eradication of H. pylori and VDR rs7975232 gene polymorphisms, the success of eradication was more prevalent in AC gene polymorphism (54.4%) vs non-responders (30.4%), while all patients (14) with gene AA (17.7%) are responders to standard treatment, while the failure of treatment was more prevalent in CC gene polymorphism (69.2% in non-responder vs 27.8% in responders) which is statistically significant. Our findings demonstrated a strong correlation between patients’ responses to H. pylori treatment and polymorphisms in the VDR gene (ApaI and TaqI) (P 0.05). Conclusion As far as we are aware, this is the first study to identify a potential link between the FokI and Apal VDR polymorphism and treatment response in H pylori-positive patients. To evaluate the findings, more research with larger number of patients and different population is required.
  • MCP1, CRP and Procalcitonin as Novel Diagnostic Markers in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
    Amal Ahmed Mohamed, Wafaa Salah, Mohamed Badr Hassan, Hala H. Eldeeb, Ahmed Sobhy Adaroas, Rania Abdelmonem Khattab, Heba M. Abostate, Moataz Yousry Soliman, Eslam Habba, Sherief Abd-Elsalam, Yousry Esam-Eldin Abo-Amer
    Open Biomarkers Journal, 2022
    Background & Aims: The aim of the study was to evaluate serum c-reactive protein (CRP), ascitic procalcitonin (PCT) and monocyte chemotactic protein-1 (MCP-1) in the diagnosis of spontaneous bacterial peritonitis (SBP) in cirrhotic patients. Methods: A cross-sectional analytic study that included 199 patients with decompensated cirrhosis (101 with SBP and 98 without SBP). Patients were classified according to Child-Pugh criteria. Ascitic PCT and MCP-1 were measured by enzyme-linked immunosorbent assay. Serum CRP, liver and renal functions were assessed. Results: Three markers are significantly elevated in SBP patients than those without ascites. Using the ROC curve at AUC 0.883 and a cut-off value of >186 ng/ml, the diagnostic performance of ascitic MCP-1 level was higher than CRP (AUC 0.562) and ascitic fluid procalcitonin (AUC 0.751) in the diagnosis of SBP. The sensitivity and specificity were 86.15% and 79.59% at the cutoff of 186 ng/ml for MCP-1, 65.4 and 75.5 at ≥ 1 ng/ml for PCT, and 52.5 and 64.3, respectively for at 11.2 mg/dl CRP. Conclusion: Ascitic MCP-1 has a better diagnostic value with higher sensitivity and specificity in diagnosis SBP compared to CRP and procalcitonin which has higher diagnostic accuracy than CRP. Further studies with a large number will be necessary to evaluate the usefulness of these markers in diagnosis, follow-up and relation to morbidity and mortality of SBP patients.
  • Diagnosis of inflammatory bowel disease by abdominal ultrasound and color doppler techniques
    Rehab Ahmed, Hossam Debian, Mohamed Fawzi, Heba Fadl Elsergany, Moataz Yousry Soliman, Ahmed Abdel Haleem Mohmed, Alaa Kandil, Mostafa Bedair Elmaghraby, Sherief Abd-Elsalam, Yousry Esam-Eldin Abo-Amer
    Current Medical Imaging, 2021
    Background & Aims: The utility of ultrasound and color Doppler in the diagnosis and evaluation of inflammatory bowel diseases (IBD) has not been studied enough. Therefore, the aim of the current study was to evaluate the importance of conventional abdominal ultrasound and color Doppler in diagnosing IBD and assessing disease activity. Methods: The study was conducted at the National Hepatology and Tropical Medicine Research Institute (NHTMRI) between July 2018 and January 2019, in which 150 patients were suffering from diarrhea, dysentery, tenesmus, or rectal bleeding were evaluated by colonoscopy, high-resolution ultrasound, and color Doppler scans. Results: The present study was conducted on 150 patients; 84 (56%) had ulcerative colitis (UC), 16 (10.7%) had Crohn's disease (CD), and 50 (33.3%) had normal colonoscopy results with a mean age 37.2 ± 9.059. The superior mesenteric Artery Peak Systolic Velocity (SMA-PSV) and End Diastolic Velocity (EDV) were significantly higher in both UC and CD than in the control group; however, pulsatility index (PI) was significantly higher in the control group than both UC and CD. However, there was no significant difference between UC and CD. The inferior mesenteric artery PSV and EDV were significantly higher in both UC and CD than in the control group. Conclusions: Doppler ultrasound findings of SMA and IMA correlate with the incidence of inflammatory bowel disease, the site of disease, and its activity.
  • Hla-dq gene polymorphisms associated with hepatitis b virus in patients with hepatocellular carcinoma progression
    Amal A. Mohamed, Adel A.-H. Abdel-Rahman, Somia Saad, Shrook Mousa, Omnia Tantawi, Fawkia E. Zahran, Nevine F. Shafik, Reham A.A. Elshimy, Ayman A.-H. Alkhalegy, Alaa Kandil, Rehab Ahmed, Mahmoud Khalil, Moataz Y. Soliman, Yousry E.-E. Abo-Amer, Sherief Abd-Elsalam
    Current Cancer Therapy Reviews, 2021
    Background: The development and progression of hepatitis B (HBV)-related disease can lead to liver cirrhosis and hepatocellular carcinoma (LC and HCC, respectively). Human leukocyte antigen (HLA) DQ polymorphism has been reported in other recent studies to deal with the association between HBV and liver disease. Our study on the Egyptian population was introduced to assess the strong association between HLA-DQ polymorphism and HBV infection in addition to the progression of HCC. Aim: The aim of this work was to estimate HLA-DQ gene polymorphisms in HBV and HCC. Methods: HLA-DQ genotype polymorphism was assayed by using the ABI Taq Man allelic discrimination assay in different groups in this study. According to the relevant HLA Class II single nucleotide polymorphism (SNP) literature, one single nucleotide polymorphism (SNPs) was selected as the candidate site; it was an HLA-DQ, which showed minor allele frequencies AA, GA, and GG. Results: Haplotype analysis was performed on all the subjects in the study; AA haplotype was the most frequent haplotype in HCC cases (18%) in comparison with HBV and healthy individuals (3%). The haplotype GA was more frequent in the HCC group and slightly more frequent in LC when compared to HBV only cases and also when compared to the control group. In contrast, the GG haplotype was recorded less frequently in HCC individuals, but the HBV and LC groups showed more frequency of this haplotype compared with the HCC group. There was a correlation between AFP serum levels and the frequency of GA and AA polymorphism in HCC cases. Conclusion: We found that AA and GA haplotype was significantly most frequent in HCC. Our findings suggest that HLA-DQ AA and GG polymorphism might serve as a novel potential predictive marker for HCC and may function in tumorigenesis of HBV.
  • Efficacy and safety of ombitasvir/paritaprevir/ ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease A real-life experience
    Sherief Abd-Elsalam, Yousry Esam-Eldin Abo-Amer, Mohamed El-Abgeegy, Samah A. Elshweikh, Heba Fadl Elsergany, Rehab Ahmed, Mahmoud Elkadeem, Nehad Hawash, Shaimaa Soliman, Rehab Badawi, Ayman Mohammed Abdou Elguindy, Moataz Yousry Soliman, Ahmed Abdelhaleem Mohmed, Loai Mansour
    Medicine United States, 2020
    Treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease was difficult in the past because of the use of interferon (IFN). It was associated with high risk IFN-related adverse reactions due to reduced renal clearance of IFN. This study aimed to evaluate the antiviral efficacy, safety, and tolerability of ombitasvir/paritaprevir/ritonavir/ribavirin in chronic kidney disease patients infected with chronic HCV. This observational, open-label prospective study was carried out on 103 patients infected chronic HCV with different grades of renal impairment. Paritaprevir/ritonavir and ombitasvir (75/50/12.5 mg) twice daily plus ribavirin were given to the patients for 12 weeks. Dose adjustment of ribavirin was done according to degree of renal impairment. Sustained virological response (12 weeks after the end of treatment) occurred in 101 patients (98.1%). Anemia occurred in 48 patients. No serious adverse events were observed in any patient. Paritaprevir/ritonavir and ombitasvir plus ribavirin for 12 weeks was considered to be safe and effective in the treatment of chronic HCV infected patients with varying degrees of renal impairment.

RECENT SCHOLAR PUBLICATIONS

  • Single operator cholangioscopy-guided lithotripsy compared to endoscopic papillary large balloon dilatation in the management of difficult common bile duct stones
    AF Abd El-Gawad, MM Azab, M Ghoname, E Ammar, A Ghazy, ...
    Al-Azhar International Medical Journal 2026 (3), 14-18 , 2026
    2026
  • Flaxseed oil and probiotics protect against induced nonalcoholic fatty liver disease (NAFLD) in male rats
    HA El Rabey, MJ Balgoon, MA Alsieni, AI Alalawy, MY Soliman, ...
    Open Life Sciences 21 (1), 20251255 , 2026
    2026
  • P1268 Impact of religion fasting on the condition of Inflammatory Bowel Disease: primary results of a multicenter multinational study
    P Alavi Nejad, N Ebrahimi Daryani, E Ramezani, ...
    Journal of Crohn’s and Colitis 20 (Supplement_1), jjaf231. 1449 , 2026
    2026
  • The Role of Endoscopic Ultrasound in Identifying Causes of Unexplained Common Bile Duct Dilation on Imaging
    MY Soliman, HAE Rashed, HAA Yahya, M Ghoname, M Elshair
    Al-Azhar International Medical Journal 2025 (12), 191-197 , 2025
    2025
  • Role of Transient Elastography Through Controlled Attenuation Parameter (CAP) in Assessment of The Stratification of Subclinical Cardiovascular Diseases Risk in NAFLD Patients
    MR Rashed, ASM Mohey Eldin, GAE Aboufarag, OM Abdelrazik, ...
    Al-Azhar International Medical Journal 2025 (9), 285-290 , 2025
    2025
  • Evaluation of Gastroesophageal Reflux Disease After Bariatric Surgery
    RH Mansour, MAA Elhawary, OM Abdel Razek, MF Elbasyony, MH Elsisi, ...
    Al-Azhar International Medical Journal 2025 (7), 180-185 , 2025
    2025
  • Expression of CD47, Aldehyde Dehydrogenase, and SOX4 Stem Cells in Different Colonic Lesions
    MAESAEF Badran, MS Rozik, OA Hammam, MAA EL Hawary, MH El Sisi, ...
    Al-Azhar International Medical Journal 2025 (4), 272-277 , 2025
    2025
  • Usage of Trapezoid RX Wire Guided Retrieval Basket with the Alliance™ II Inflation Handle for Treatment of Bouveret Syndrome: A Rare Clinical Entity
    M Ghoname, H Abosheaishaa, A Sethi, S Abbas, S Hegab, MY Soliman
    ASIDE Gastroenterology 1 (1), 1-4 , 2025
    2025
  • A comparative survey study of knowledge, attitude, and practice towards medical ethics among surgical and non-surgical physicians
    HK Khalifa, AA Wahdan, MY Soliman, FG Sobeeh
    Egyptian Journal of Forensic Sciences 14 (1), 42 , 2024
    2024
    Citations: 1
  • Covert hepatic encephalopathy: a neglected topic—a narrative review
    M Elbadry, AA Baki, A bakr, EA Elhamrawy, H Abdel-Tawab, A Aish, ...
    Egyptian Liver Journal 14 (1), 59 , 2024
    2024
    Citations: 3
  • Covert hepatic encephalopathy: a neglected topic—a narrative review
    A Aish, I Nooh, A Adel, MY Soliman, N Mohammed, S Zaky
    2024
  • Bowel Ultrasound Versus Computed Tomography Enterography in Egyptian Patients with Different Colonic Disorders
    IA Ismail, A Waheeb, SF Mohamed, M Salah EL-Din, A Hendawy, ...
    Al-Azhar International Medical Journal 5 (10), 18 , 2024
    2024
  • Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysis
    H Abosheaishaa, M Hussein, M Ghallab, M Abdelhamid, N Balassiano, ...
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews 18 (1), 102938 , 2024
    2024
    Citations: 35
  • Association between vitamin D receptor polymorphism and the response to Helicobacter Pylori treatment
    YEE Abo-Amer, AA Mohamed, MM Elhoseeny, SM Rezk, S Abdel-Salam, ...
    Infection and Drug Resistance, 4463-4469 , 2023
    2023
    Citations: 6
  • Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis
    H Abosheaishaa, I Mohamed, M Ghallab, A Alzamzamy, N Balassiano, ...
    The Liver Meeting 2023 , 2023
    2023
    Citations: 1
  • Primary localized ileal amyloidosis with chronic ileitis: a case report with review of literature
    M Ghoname, H Abosheaishaa, M Shehata, M Abdelwahed, MY Soliman
    The Egyptian Journal of Internal Medicine 35 (1), 53 , 2023
    2023
  • The Value of Thioredoxin Level and its Gene Polymorphism in the Diagnosis of Post-HCV Hepatocellular Carcinoma
    HS Alegaily, MY Soliman, AM Gad, EAM Abou-Omar, M Saleh, ...
    Current Cancer Therapy Reviews 19 (1), 67-73 , 2023
    2023
  • MCP1, CRP and Procalcitonin as Novel Diagnostic Markers in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
    AA Mohamed, W Salah, MB Hassan, HH Eldeeb, AS Adaroas, RA Khattab, ...
    The Open Biomarkers Journal 12 (1) , 2022
    2022
    Citations: 3
  • Diagnosis of inflammatory bowel disease by abdominal ultrasound and color Doppler techniques
    R Ahmed, H Debian, M Fawzi, HF Elsergany, MY Soliman, AAH Mohmed, ...
    Current Medical Imaging Reviews 17 (9), 1085-1093 , 2021
    2021
    Citations: 11
  • HLA-DQ Gene Polymorphisms Associated with Hepatitis B Virus in Patients with Hepatocellular Carcinoma Progression
    AA Mohamed, AAH Abdel-Rahman, S Saad, S Mousa, O Tantawi, ...
    Current Cancer Therapy Reviews 17 (1), 75-81 , 2021
    2021
    Citations: 1

MOST CITED SCHOLAR PUBLICATIONS

  • Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: A systematic review and meta-analysis
    H Abosheaishaa, M Hussein, M Ghallab, M Abdelhamid, N Balassiano, ...
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews 18 (1), 102938 , 2024
    2024
    Citations: 35
  • Diagnosis of inflammatory bowel disease by abdominal ultrasound and color Doppler techniques
    R Ahmed, H Debian, M Fawzi, HF Elsergany, MY Soliman, AAH Mohmed, ...
    Current Medical Imaging Reviews 17 (9), 1085-1093 , 2021
    2021
    Citations: 11
  • Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience
    S Abd-Elsalam, YEE Abo-Amer, M El-Abgeegy, SA Elshweikh, ...
    Medicine 99 (42), e21972 , 2020
    2020
    Citations: 7
  • Association between vitamin D receptor polymorphism and the response to Helicobacter Pylori treatment
    YEE Abo-Amer, AA Mohamed, MM Elhoseeny, SM Rezk, S Abdel-Salam, ...
    Infection and Drug Resistance, 4463-4469 , 2023
    2023
    Citations: 6
  • Diagnostic value of plasma m2-pyruvate kinase in Egyptian patients with colorectal cancer
    AA Wahib, MS Seif El-Nasr, MB Ismail, DM Eltiby, SAE Sayed, ...
    The Egyptian Journal of Hospital Medicine 73 (11), 7997-8006 , 2018
    2018
    Citations: 6
  • Covert hepatic encephalopathy: a neglected topic—a narrative review
    M Elbadry, AA Baki, A bakr, EA Elhamrawy, H Abdel-Tawab, A Aish, ...
    Egyptian Liver Journal 14 (1), 59 , 2024
    2024
    Citations: 3
  • MCP1, CRP and Procalcitonin as Novel Diagnostic Markers in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
    AA Mohamed, W Salah, MB Hassan, HH Eldeeb, AS Adaroas, RA Khattab, ...
    The Open Biomarkers Journal 12 (1) , 2022
    2022
    Citations: 3
  • Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience
    G Soliman, MS Negm, M Elzalabany, AA Malik, A Khattab, M Elshair, ...
    J Hepatol 68, S276 , 2018
    2018
    Citations: 2
  • A comparative survey study of knowledge, attitude, and practice towards medical ethics among surgical and non-surgical physicians
    HK Khalifa, AA Wahdan, MY Soliman, FG Sobeeh
    Egyptian Journal of Forensic Sciences 14 (1), 42 , 2024
    2024
    Citations: 1
  • Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis
    H Abosheaishaa, I Mohamed, M Ghallab, A Alzamzamy, N Balassiano, ...
    The Liver Meeting 2023 , 2023
    2023
    Citations: 1
  • HLA-DQ Gene Polymorphisms Associated with Hepatitis B Virus in Patients with Hepatocellular Carcinoma Progression
    AA Mohamed, AAH Abdel-Rahman, S Saad, S Mousa, O Tantawi, ...
    Current Cancer Therapy Reviews 17 (1), 75-81 , 2021
    2021
    Citations: 1
  • Single operator cholangioscopy-guided lithotripsy compared to endoscopic papillary large balloon dilatation in the management of difficult common bile duct stones
    AF Abd El-Gawad, MM Azab, M Ghoname, E Ammar, A Ghazy, ...
    Al-Azhar International Medical Journal 2026 (3), 14-18 , 2026
    2026
  • Flaxseed oil and probiotics protect against induced nonalcoholic fatty liver disease (NAFLD) in male rats
    HA El Rabey, MJ Balgoon, MA Alsieni, AI Alalawy, MY Soliman, ...
    Open Life Sciences 21 (1), 20251255 , 2026
    2026
  • P1268 Impact of religion fasting on the condition of Inflammatory Bowel Disease: primary results of a multicenter multinational study
    P Alavi Nejad, N Ebrahimi Daryani, E Ramezani, ...
    Journal of Crohn’s and Colitis 20 (Supplement_1), jjaf231. 1449 , 2026
    2026
  • The Role of Endoscopic Ultrasound in Identifying Causes of Unexplained Common Bile Duct Dilation on Imaging
    MY Soliman, HAE Rashed, HAA Yahya, M Ghoname, M Elshair
    Al-Azhar International Medical Journal 2025 (12), 191-197 , 2025
    2025
  • Role of Transient Elastography Through Controlled Attenuation Parameter (CAP) in Assessment of The Stratification of Subclinical Cardiovascular Diseases Risk in NAFLD Patients
    MR Rashed, ASM Mohey Eldin, GAE Aboufarag, OM Abdelrazik, ...
    Al-Azhar International Medical Journal 2025 (9), 285-290 , 2025
    2025
  • Evaluation of Gastroesophageal Reflux Disease After Bariatric Surgery
    RH Mansour, MAA Elhawary, OM Abdel Razek, MF Elbasyony, MH Elsisi, ...
    Al-Azhar International Medical Journal 2025 (7), 180-185 , 2025
    2025
  • Expression of CD47, Aldehyde Dehydrogenase, and SOX4 Stem Cells in Different Colonic Lesions
    MAESAEF Badran, MS Rozik, OA Hammam, MAA EL Hawary, MH El Sisi, ...
    Al-Azhar International Medical Journal 2025 (4), 272-277 , 2025
    2025
  • Usage of Trapezoid RX Wire Guided Retrieval Basket with the Alliance™ II Inflation Handle for Treatment of Bouveret Syndrome: A Rare Clinical Entity
    M Ghoname, H Abosheaishaa, A Sethi, S Abbas, S Hegab, MY Soliman
    ASIDE Gastroenterology 1 (1), 1-4 , 2025
    2025
  • Covert hepatic encephalopathy: a neglected topic—a narrative review
    A Aish, I Nooh, A Adel, MY Soliman, N Mohammed, S Zaky
    2024